SOLID TUMOR CANCER

This study tests a personalized vaccine (Neo-DC) made from a patient's own immune cells to target unique markers on their advanced solid tumor. The vaccine aims to teach the immune system to attack the cancer. The trial enrolls 9 adults with advanced solid tumors who have not res…

This study tests a new drug called AVZO-1418 in people with advanced solid tumors that have spread. The main goals are to find a safe dose and see if the drug can shrink tumors. About 480 adults will take part in this first human trial.

This early-stage study tests a new drug, PLT012, in 36 adults with advanced solid tumors that have not responded to other treatments. The main goal is to find safe doses and check for side effects. Researchers will also measure drug levels in the blood and see if tumors shrink. A…

This early-phase study tests an experimental drug called WTX212A in 12 people with advanced solid tumors. The drug is given alone or with radiotherapy to see if it shrinks tumors and is safe. The goal is to find the best dose and understand side effects.

This study tests a new drug called AVZO-103 in people with advanced bladder cancer or other solid tumors that have spread. The drug is designed to attack cancer cells directly. The main goals are to check safety, find the best dose, and see if it shrinks tumors. About 355 adults …

This study tests two drugs, IN10018 and RNK08954, given together to people with advanced solid tumors that have a specific genetic change called KRASG12D. The goal is to find the best dose and see if the combination can shrink tumors. About 92 adults with locally advanced or meta…

This study is for people with advanced or metastatic solid tumors, including non-small cell lung cancer, who have not responded to other treatments. It tests a combination of two drugs: HLX43 (an antibody-drug conjugate targeting PD-L1) and serplulimab (an immunotherapy). The goa…

This study tests an experimental drug called GV20-0251 in adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug can shrink or control the tumors. About 350 participants will take part in this early-phase trial.

This early-phase trial tests an investigational drug called SYS6043 in adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers will also look for signs that the …

This study tests a combination of two drugs—Lutathera (a targeted radiation therapy) and olaparib (a PARP inhibitor)—in children and teens aged 3 to 18 with solid tumors that have come back or not responded to standard treatment. The goal is to find the safest dose and see if the…

This early-phase trial is testing a new treatment called TC-G203 for people with advanced solid tumors that have a specific marker (GPC3) and have not responded to standard therapies. The main goal is to find the safest dose and check for side effects. About 30 adults will take p…

This study tests whether eating all meals within an 8-hour window each day can improve how well cancer treatments work and reduce side effects. It will enroll 100 Alaska Native or American Indian adults with breast or rectal cancer. Participants will follow this time-restricted e…

This study tests whether a mobile app that tracks symptoms and sensor data can help people receiving chemotherapy feel better and stay connected with their care team. About 50 adults with solid tumors will use the app and a Fitbit for 90 days. The goal is to see if the app is eas…

This study tests a program that screens cancer patients for emotional distress and refers them to mental health services. It involves 50 English- or Spanish-speaking adults with a new solid tumor cancer diagnosis at Jamaica Hospital Medical Center. The goal is to see if the progr…

This study looks at DNA methylation patterns in brain, thyroid, and endometrial tumors to better understand how these cancers work. Researchers will analyze tumor samples from 180 adults to find unique epigenetic signatures that could help classify tumors and guide treatment. The…

This study is testing whether a blood test that looks for tiny bits of tumor DNA (ctDNA) can find cancer early after treatment. Researchers will follow about 100 people with different solid tumors, plus healthy volunteers, to see if the test helps predict when cancer comes back. …

This study is for people with advanced cancers that are no longer responding to standard treatments. Researchers will take a small sample of the tumor and grow it in the lab to test which drugs might work best. The goal is to see if this approach can help doctors choose more effe…